Research Insights

Why Jurisdiction Shapes Regulatory Classification More Than Business Model Preference Alone A supplier comparing compounding pharmacy demand purely by business model, direct versus distributor-led, is skipping the constraint that actually narrows the field first. Within the north america compounding pharmacy market, jurisdiction is decided first, since whether a pharmacy operates in the US o

Why Sterility Requirements Drive Compounding Type Fit First A buyer comparing compounding pharmacy supplies purely by product/supply category, APIs versus equipment, is skipping the constraint that actually narrows the field first. Within the north america compounding pharmacy market, sterility requirements are decided first, since whether a formulation requires sterile or non-sterile handli

The US 505(b)(2) Specialty Pharma Developer Landscape Twelve companies are profiled in the full report, and they are not all in the same business despite appearing in the same landscape. Within the united states 505(b)(2) specialty pharmaceuticals market, the developer base divides into two types that reach specialty pharma buyers in genuinely different ways. This page introduces those tw

Why Go-to-Market Channel Signals Commercial Relationships More Than Therapeutic Focus Alone A developer comparing 505(b)(2) commercialization purely by therapeutic focus, CNS versus orphan, is skipping the constraint that actually determines commercial fit first. Within the united states 505(b)(2) specialty pharmaceuticals market, go-to-market channel is decided first, since a direct commerc

Why Development Stage Determines Commercial Readiness Before Therapeutic Focus Does A buyer comparing 505(b)(2) demand purely by therapeutic focus, CNS versus orphan, is skipping the constraint that actually narrows commercial readiness first. Within the united states 505(b)(2) specialty pharmaceuticals market, development stage is decided first, since a preclinical CNS programme and a precl

Why Developer Resourcing Model Shapes Business Model More Than Pathway Preference Alone A developer comparing 505(b)(2) strategies purely by regulatory pathway, pure NDA versus hybrid ANDA, is skipping the constraint that actually narrows the field first. Within the united states 505(b)(2) specialty pharmaceuticals market, developer resourcing model is decided first, since a developer's

Why Unmet Clinical Need Drives Delivery Technology Choice First A developer comparing 505(b)(2) products purely by product strategy type, reformulation versus combination, is skipping the constraint that actually narrows the field first. Within the united states 505(b)(2) specialty pharmaceuticals market, unmet clinical need is decided first, since what clinical gap a given programme address

Thirteen companies are profiled in the full report, and they are not all in the same business despite appearing in the same landscape. Within the global clinical trial imaging in oncology market, the provider base divides into two types that reach sponsors in genuinely different ways. This page introduces those two types and describes each company by what kind of business it is. It contai

A provider comparing clinical trial imaging demand purely by trial phase, Phase I versus Phase III, is skipping the constraint that actually determines fit first. Within the global clinical trial imaging in oncology market, customer type is decided first, since a pharmaceutical company and a government/cooperative oncology group generate fundamentally different supplier relationship needs, inde

A sponsor comparing clinical trial imaging demand purely by oncology indication, lung versus breast cancer, is skipping the constraint that actually narrows imaging complexity first. Within the global clinical trial imaging in oncology market, trial phase is decided first, since a Phase I trial in one oncology indication and a Phase I trial in another can share more in common by imaging complex